SCHEMBL11276473

SCHEMBL11276473

CC(N)Cc1c(Cl)cccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.54
SLC6A3 Q01959 3/20 0.54
PNMT P11086 3/20 0.53
TAAR1 Q96RJ0 5/20 0.52
SLC6A4 P31645 2/20 0.52
MAOA P21397 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
CYP2A6 P11509 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA1 P30542 1/20 0.52
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
NFKB1 P19838 1/20 0.47
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13692457 1.00 SLC6A2 (0.54) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL2222710 0.86 TAAR1 (0.56) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL5018858 0.81 TAAR1 (0.44) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL19831978 0.80 SLC6A2 (0.47) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL2426412 0.77 AKR1B1 (0.43) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL15083012 0.77 AKR1B1 (0.43) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL18537078 0.77 TAAR1 (0.41) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL8790684 0.77 TAAR1 (0.46) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL3885817 0.77 PNMT (0.57) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL13692532 0.77 PNMT (0.57) SLC6A2SLC6A3PNMTTAAR1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2024-05-30 US disclosed
EP-0064487-A1 New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure Aktiebolaget Hässle (SE) 1982-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME PPM1A, PPP2CA, PPP3CA SLC6A2 3829/4885SLC6A3 4551/4885PNMT 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.